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ultimately leading to death. The whole pro-
cess is characterized by the progressive loss 
of immune competence, in particular cellu-
lar immunity, as evidenced by the decline in 
phenotype CD4+ T cells.
Today, therapeutic regimens currently used 
for the treatment of HIV infection, identified 
with the acronym Highly Active Antiretrovi-
IntroductIon
The typical natural course of untreated HIV 
starts from an acute phase of 1-2 weeks, with 
flu-like symptoms, followed by a clinically 
silent phase of varying duration, usually up to 
5 to 12 years, followed by a worsening series 
of clinical events, defining the Acquired Im-
mune Deficiency Syndrome (AIDS) [1] and 
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AbstrAct
BACKGROUND: Highly Active Antiretroviral Therapy (HAART) has transformed HIV into a lifelong condition. Follow-
ing the chronicity of the disease, and significant increase in lifespan – the prevalence of comorbidities increased in HIV+ 
subjects that are exposed both to a higher risk of developing cardiovascular disease, renal disease, osteopenia/osteoporosis 
and diabetes, and to the risk of developing them early. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fuma-
rate (E/C/F/TAF), a complete, Single-Tablet antiretroviral Regimen (STR) that combines the effectiveness and tolerability 
of integrase inhibitors with an innovative backbone was recently introduced in Italy. Compared to Tenofovir Disoproxil 
Fumarate (TDF), TAF reaches the sites of action more efficiently, reducing tenofovir plasma concentration to more than 
90% and the risk of off-target effects.
OBJECTIVE: A patient-level micro-simulation model was adapted to the Italian context to evaluate E/C/F/TAF cost-
effectiveness vs three boosted regimens for HIV+ patients treatment. 
METHODS: A Markov micro-simulation model was adapted to the Italian context for the evaluation of the cost-effective-
ness in patients with HIV. The total cost per patient accounts for drug therapies and the management of adverse events and 
comorbidities. The quality-adjusted life expectancy (in QALYs) is calculated by weighing the years of life lived by the 
utility weights. A 70-year time horizon was adopted to simulate a lifetime analysis; shorter time horizons were considered 
in the sensitivity analyses. 3.5% discount rate was applied both for costs and future benefits. The rate of virologic suppres-
sion at 48 weeks with E/C/F/TAF is 92.3%; for the other treatments such proportion is calculated by applying to the refer-
ence rate the relative risks, as calculated in a recent network meta-analysis (NMA). Alternative treatments considered in 
this analysis are three boosted regimens commonly used in Italy: tenofovir disoproxil fumarate/emtricitabine/elvitegravir/
cobicistat in STR; tenofovir disoproxil fumarate/emtricitabine + darunavir/ritonavir; tenofovir disoproxil fumarate/emtric-
itabine + atazanavir/ritonavir.
RESULTS: E/C/F/TAF improves survival and quality of life (20.17 LY and 14.89 QALY), with the lowest total cost (€ 
280,528), thus resulting dominant over three comparators considered as starting therapy. The sensitivity analysis confirms 
the results of the base case: at a willingness-to-pay threshold of € 30,000 per QALY, the E/C/F/TAF strategy is the most 
cost-effective, with a 90% probability and it is the most cost-effective even with a threshold of € 10,000 per QALY, with a 
50% probability.
CONCLUSION: E/C/F/TAF can be a sustainable alternative to currently available treatments, combining the advantage of 
the STR to lower risks of kidney and bone damage than observed in regimens based on TDF.
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vative backbone containing emtricitabine 
and Tenofovir Alafenamide Fumarate (TAF). 
Compared to Tenofovir Disoproxil Fumarate 
(TDF), the molecules contained in the previ-
ously approved therapies, TAF is converted 
into tenofovir (the active ingredient) at lym-
phocytic level more efficiently, so that teno-
fovir concentrates at the site of action, rather 
than persisting in the plasma. This change 
allows a reduction of more than 90% in the 
plasma concentration of tenofovir, whose 
metabolism is associated with adverse bone 
and kidney effects.
In summary, TAF-based regimens maintain 
the same high level of efficacy observed 
with TDF, with reduced side effects [5]. As 
a consequence, patient long-term outcomes, 
including persistence with therapy, may be 
improved at the same time that the costs as-
sociated with treatment failure and of manag-
ing off-target effects are reduced.
E/C/F/TAF therefore presents a series of 
characteristics that potentially have positive 
effects from a pharmacoeconomic perspec-
tive: high intrinsic effectiveness (as measured 
in RCTs), simple administration regimen 
(STR), which is known to be associated with 
improved adherence, and a more tolerable 
safety profile, all factors that contribute to the 
high level of effectiveness observed in clin-
ical practice.
The data available so far in the literature cor-
roborate these expectations, with indications 
of a reduction in the risk of hospitalizations 
for concomitant HIV, with a higher quality-
adjusted life expectancy, compared to multi-
tablet regimens [6].
The aim of this work is to assess the Incre-
mental Cost-Effectiveness Ratio (ICER) 
of E/C/F/TAF compared to TDF regimens 
containing a booster (ritonavir or cobicistat) 
since they are the most frequent used in the 
Italian clinical practice for patients with HIV-
1 virus. Ideally E/C/F/TAF is an alternative 
to Tenofovir Disoproxil Fumarate/emtric-
itabine/elvitegravir boosted with cobicistat 
(TDF/FTC-EVG/c) in STR and to Tenofo-
vir Disoproxil Fumarate/emtricitabine + da-
runavir or atazanavir boosted with ritonavir 
(TDF/FTC-DRV/r or -ATV/r).
Methods
A patient-level micro-simulation model de-
veloped for United Kingdom [7] was adapted 
to the Italian context for evaluation of the 
cost-effectiveness of treatments in patients 
with HIV. The model was developed in R, 
with input/output interface in MS Excel®. A 
cohort of 1,000 patients was simulated us-
ing a Markov model over a time horizon of 
ral Therapy (HAART) in general are based on 
the combination of three antiretroviral drugs 
(a “backbone” of two Nucleoside and/or 
Nucleotide Reverse Transcriptase Inhibitors 
– NRTIs, plus a third agent: NRTI, Integrase 
Inhibitor – INI, or Protease Inhibitors – PI). 
The HAART introduction and consequent 
widespread use since 1996 has profoundly 
changed the clinical course of HIV disease, 
transforming HIV-positive status from a pre-
cursor of AIDS and high mortality into a 
manageable lifelong condition. Therapeutic 
success is strongly correlated with continu-
ous administration of AntiRetroviral Therapy 
(ART) and lifelong high levels of adherence. 
However – due to the chronicity of the dis-
ease, and in particular because of a signifi-
cant increase in lifespan – the prevalence of 
Non-AIDS Related Morbidities (NARMs) 
has increased in HIV-infected individuals. 
Compared to the general population, HIV 
infection is associated with a higher [2] risk 
of developing cardiovascular disease, kidney 
disease, osteopenia/osteoporosis, diabetes 
and neuropsychiatric disorders, and to the 
risk of developing these earlier than seen in 
the general population [3].
It should also be emphasized that the high 
impact of the cost of ART itself [4], the risk 
of developing resistance and the switch be-
tween treatments – possibly required by the 
occurrence of adverse events or by a thera-
peutic failure – all contribute to exacerbate 
the burden of the disease for the National 
Health Service.
An appropriate and informed choice of 
therapeutic regimens can help improve the 
effectiveness of the prescription, reduce the 
risk of virologic failure, and reduce resource 
burden, including potentially more expen-
sive subsequent ART regimens. From this 
standpoint, the recent developments in ART 
have focused on the combination of three ac-
tive molecules in a single tablet (Single Tab-
let Regimen – STR), with the objective of 
simplifying administration and maximizing 
adherence to treatment. Studies have dem-
onstrated that improved adherence to therapy 
significantly reduces the risks of treatment 
failure in its various forms, including a lower 
risk of developing resistance to the antiretro-
viral drugs.
A recent introduction in the Italian market 
is a new once daily fixed combination tablet 
containing a complete ART regimen E/C/F/
TAF: Elvitegravir (E) + Cobicistat (C) + Em-
tricitabine (F) + Tenofovir Alafenamide Fu-
marate (TAF).
E/C/F/TAF is presented as a complete STR 
that combines the effectiveness and toler-
ability of integrase inhibitors with an inno-
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gin a treatment based on a dual NRTI back-
bone and a third drug chosen from among PIs, 
INIs or NNRTIs (Non-Nucleoside Reverse 
Transcriptase Inhibitors). In this model, the 
new formulation in the STR E/C/F/TAF was 
compared with the following three regimens:
 - TDF/FTC-EVG/c: Tenofovir Disoprox-
il Fumarate/emtricitabine/elvitegravir 
(boosted with cobicistat) in STR.
 - TDF/FTC-DRV/r: Tenofovir Disoprox-
il Fumarate/emtricitabine + darunavir 
(boosted with ritonavir)
 - TDF/FTC-ATV/r: Tenofovir Disoproxil 
Fumarate/emtricitabine + atazanavir 
(boosted with ritonavir)
All of these comparator regimens were char-
acterized by the presence of a pharmacoki-
netic booster, which enhances the absorption 
of the substrate and reduces its elimination. 
One of the comparators was a regimen also 
incorporating EVG (elvitegravir), COBI (co-
bicistat) booster and FTC (emtricitabine), but 
differing by containing TDF rather than the 
newer TAF. In the other two comparators, PIs 
were associated with RTV (ritonavir) booster. 
For all comparators, the nucleoside/nucleo-
tide backbone was represented by TDF and 
FTC. The perspective of this comparison 
therefore refers to the search for overall dif-
ferential therapeutic performance elements 
between a brand new, single-tablet therapeu-
tic formulation – characterized in particular 
by the presence of TAF – and three TDF-
based regimens currently in common us-
age in Italy (although TDF/FTC-DRV/r and 
TDF/FTC-ATV/r have been recently recom-
mended for particular conditions only).
70 years, discretized into monthly cycles (30 
days). A simplified diagram of the model is 
provided in Figure 1.
The evolution of patients’ treatment, between 
the recommended pharmacological therapies 
(in accordance with the guidelines for the 
management of HIV-positive patients [8]), 
occurred via the likelihood of viral suppres-
sion associated with each treatment, CD4 
level determined the risk of Opportunistic 
Infections (OIs) and neoplasms, and placed 
simulated patients into one of the three cat-
egories for the use of outpatient resources.
 - Complex Patients (HIV3): Patients with 
AIDS who need additional management 
of ARV or patients with persistent vire-
mia.
 - New patients (HIV1): patients under 
combination ART (cART) treatment for 
less than a year without HIV3.
 - Stable Patients (HIV2): Unclassified pa-
tients such as HIV1 or HIV3.
The risk of NARM was calculated using pub-
lished regressions specific for each adverse 
event (cardiovascular [9], renal [10], diabetes 
[11], hypertension [12]) or, in the case of risk 
of fracture, on the base of a cohort analysis of 
883 treated PLHIV (People Living with HIV) 
[13]. According to this model, the risks of 
Treatment-Related Adverse Events (TRAEs) 
were independent of the CD4 count, but did 
depend on the antiretroviral therapy the pa-
tient was receiving. Mortality was calculated 
on the basis of the adverse events simulated 
in the model (specific for OIs and neoplasms, 
while for TRAEs, mortality was calculated 
in accordance with the natural mortality of 
the Italian population, multiplied by specific 
relative risks).
Pharmacological treatments could be dis-
continued due to virological failure, or lack 
of suppression. In this case the choice of the 
treatments following the first line (up to the 
fourth line of treatment) was made through 
a semi-deterministic algorithm, depending on 
the previous treatments and their tolerability 
and resistance (see section 2.4 in the text).
The total cost per patient was calculated by 
economically valuing the drug therapies 
and the management of adverse events and 
comorbidities. The quality of life was calcu-
lated by weighing the years of life lived by 
the utility weights, which are a function of 
the patients’ baseline characteristics and their 
therapeutic and disease course (see para-
graph Progression between therapeutic 
lines section).
Comparators
In compliance with published clinical guide-
lines, patients with newly diagnosed HIV be-
Figure 1. Simplified diagram of the model
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ommended the application of a 3% discount 
rate for both costs, and future benefits [14]. 
The same value was indicated in the most re-
cent draft guidelines drawn up and discussed 
in 2009 by the Associazione Italiana di Eco-
nomia Sanitaria (AIES, Italian Association 
of Health Economics) [15], while the Euro-
pean Commission proposed an annual rate of 
5% [16]. The latter rate has been considered 
too high by many economists [17], however, 
and the Istituto Nazionale per l’Impatto So-
ciale dell’Economia (INISE, National In-
stitute for the Social Impact of Economy) 
recommended a discount rate lower by about 
1.5% than the official ones. Based on these 
considerations, and in line with international 
publications [18] referring to the Italian con-
text, it was decided to apply a 3.5% discount 
rate (for costs and benefits).
In order to take into account the Italian and 
European guidelines, the sensitivity analysis 
considered the 3% and 5% discount rates.
The analysis was performed from the per-
spective of the Italian National Health Ser-
vice (SSN, Servizio Sanitario Nazionale); 
therefore only the direct healthcare costs 
borne by the health system and its structures 
were taken into account. Direct non-health-
related costs borne by patients, or societal 
costs due to reduced productivity of patients 
and their caregivers, were disregarded.
Population
The analysis was conducted in a population 
of HIV patients, with a mean initial age of 36 
years. In the absence of an observational data-
base inclusive of all the characteristics of the 
population analyzed, necessary for the simu-
lation, input data were obtained from various 
published studies [8,10,18-22]. These data, 
and their sources, are summarized in Table 
I. The cohorts analyzed were comparable as 
for age, gender, mode of transmission of HIV 
and baseline CD4 count.
Progression between 
therapeutic lines
For progression between therapeutic lines, 
decision-making algorithms based on the 
opinion of clinical experts were followed. 
Within the first line treatment a patient be-
gan one of the two “paths” considered in the 
analysis: i.e. PI or INI as third agent. In cases 
of failure due to tolerability, patients were 
switched to another therapeutic path (i.e. 
the class of third agent was changed), or re-
mained on the current path, but changed the 
drug within the same third agent. The choice 
of the new drug for each treatment class oc-
curred deterministically, from a list arranged 
according to the frequency of use in the Ital-
Average sD1 source notes2
general characteristics
Age (years) 36.76 8.24 [19] N1
Gender (% males) 73.4 [19]
MSM (%) 31.1 [19]
IDU (%) 22.4 [19]
Baseline CD4 count (cells/mm3) 496.12 288.86 [19] N1
Viral load (log10copies/ml) 3.85 1.78 [19] N1
Race (%)   [19]
 • Caucasian 95.6
 • African 4.4
Initial comorbidities (%)
Diabetes 2.1 [19]
CV disease 2.9 [20]
Bone fractures 2.5 [21]
Kidney failure 0.7 [20]
Hypertension 29.4 [22]
risk factors
eGFR (ml/min/1,73 m2) 100.63 18.19 [19] N1
Smoker (%) 53.0 [23]
Former smoker (%) 14.0 [23]
Total cholesterol (mmol/l) 4.46 1.12 [19] N1
LDL (mmol/l) 2.75 0.62 N4
HDL (mmol/l) 1.12 0.35 [19] N1
Triglycerides (mmol/l) 1.68 0.87 [22] N1
Glycemia (mg/dl) 87.66 11.16 [19] N1
Systolic pressure (mm Hg) 123.26 14.69 [22] N2
Diastolic pressure (mm Hg) 78.80 9.81 [22] N2
BMI (kg/m2) 23.29 3.15 [20] N3
Family history of CV disease 9.2 [9]
HCV co-infection (%) 11.7 [20]
Family history of hypertension 
(1 parent)
4.0 [7]
Family history of hypertension 
(both parents)
1.0 [7]
Family history of diabetes 17.0 [11]
Table I. Baseline characteristics of the cohort simulated in the model
1 If not otherwise specified, standard deviation was calculated to be 10% of the average 
value
2 N1: Fitted mean and SD to more accurately fit median and IQR; N2: Mean and SD 
calculated starting from mean and SD subgroups; N3: Fitted mean and SD to more 
accurately fit median and %<18.5, %<25; N4: Calculated starting from TC and HDL 
assuming other components equal to 2/15 of TC according to UK model
BMI = Body Mass Index; eGFR = Estimated Glomerular Filtration Rate; HCV = Hepatitis 
C Virus; HDL = High Density Lipoproteins; IDU = mode of transmission “Injection Drugs 
Use”; LDL = Low Density Lipoproteins; MSM = mode of transmission “Man who have Sex 
with Man”; SD = Standard Deviation
Time horizon, discount rates 
and perspective analysis
Given the chronic nature of the disease, a 70-
year time horizon was adopted to simulate a 
lifetime analysis; shorter time horizons (5, 10, 
20, 40 years) were considered in the sensitiv-
ity analysis. The Italian guidelines for health-
care financial assessments issued in 2001 rec-
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ian clinical practice. Starting from the third 
line, in case of failure due to resistance, the 
third drug – besides being replaced – could 
be “partnered” with another drug of another 
class (e.g. a PI and an INI), or to maraviroc, 
in the most critical cases. In addition to the 
switch for intolerance and resistance, the 
model assumed that 20% of patients would 
modify the therapy if they experienced 5 or 
more TRAEs in the same month. In the lim-
ited cases where the patient had exhausted 
all possible treatments, the model provided 
for the continuation of treatment with the 
last assigned sequence of drugs, until death. 
According to the opinion of clinical experts, 
changes in the backbone are much rarer than 
the change of third agent, since the choice is 
much more limited. As such, switches be-
tween backbones, for the given failure reason 
(resistance, intolerance or non-adherence) 
were governed by an assumed proportion of 
90%, 90% and 20%, respectively.
Any switch to new treatments occurred at 
follow-up visits; by default, in the first year 
of treatment, follow up was every 3 months, 
while from the second year of treatment, if 
the CD4 count was above 200, follow up was 
every 6 months.
Clinical inputs
Effectiveness
It was assumed that the percentage of patients 
with virologic suppression (viral load less 
than 50 copies per ml) at 12 months corre-
sponds to the proportion of patients success-
fully treated, derived directly or indirectly to 
the 48 week data reported in the RCTs; al-
though this hypothesis might not be very pre-
cise from a clinical standpoint (patients can 
take 3 to 6 months to respond), the impact on 
costs and clinical outcomes is insignificant.
The rate of virologic suppression at 48 weeks 
with ECF/TAF is 92.3% [24]; for the other 
treatments, such proportion is calculated 
by applying to the reference rate the rela-
tive risks, as calculated in a recent Network 
Meta-Analysis (NMA) [25] and reported in 
Table II (only for the comparators involved 
in the analysis). Final effectiveness data for 
all possible treatments in the simulation are 
reported in Table III.
Second-line treatments were assumed to have 
the same rates of viral suppression as first-
line treatments [expert opinion], while for the 
subsequent lines, a reduction in effectiveness 
was applied (-5% in the third line and -10% 
in the fourth line).
In virological suppression, adherence to treat-
ment crucially affects success [27]. In this 
model, this trend was incorporated using the 
rates of adherence in HIV infected patients 
regimen rr 95% CI
DRV + FTC/TDF 0.96 0.89-1.02
ATV + FTC/TDF 0.92 0.89-0.97
EVG + FTC/TDF 0.98 0.95-1.01
Table II. Treatment effectiveness of first line therapeutic options
RR = Relative Risk
FTC/TAF FTC/TDF ABC/3TC Other1
RPV NA 0.905 0.9052 0.831
ETV [18] NA 0.759 0.7592 0.697
DRV NA 0.887 0.915 0.814
ATV NA 0.850 0.868 0.780
EVG 0.923 0.905 0.9052 0.831
RAL NA 0.924 0.933 0.848
DTG NA 0.952 0.933 0.873
MVC NA 0.653 0.6532 0.599
Table III. Rate of virological suppression of the treatments for second-line 
treatments considered in the analysis
1 Calculated as 8.25% less than TDF/FTC, in accordance with [26]
2 Assumed to have same virological suppression rate as the TDF/FTC combination 
Causes of failure PIs nnrTIs InIs
Sporadic blip 20.57% 7.06% 15.58%
Intolerance/drug interaction 5.07% 1.74% 3.84%
Poor adherence 73.36% 25.19% 55.57%
Resistance 1.00% 66.00% 25.00%
Loss at follow-up NA NA NA
Table IV. Causes of virological failure
INI = integrase inhibitors; NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor; 
PI = Protease Inhibitor
Average sD
Adherence (reference 100%)
< 100% 1.22 0.2168
≤ 95% 1.51 0.2169
≤ 80% 1.70 0.2781
≤ 65% 1.75 0.3138
Previous failures due to drug resistance (reference 0)
1 1.39 0.2704
> 1 1.68 0.7730
Drug class (reference nnrTIs)
PI 1.28 0.1658
Other 0.75 0.2423
Table V. Risks related to late failure
NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor; PI = Protease Inhibitor 
SD = Standard Deviation
with, and without, virological failure (36.8% 
and 89.2%, respectively) [28]. In addition, 
for patients treated with a STR, a 4.5% in-
crease in adherence was expected [29].
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where intercept ɑ and shape parameter λ are 
specific to each of the 19 AIDS-related dis-
orders highlighted in the study (Table VIII).
Treatment Related Adverse Events
Treatment-related adverse events (TRAEs) 
were divided into the following categories: 
central nervous system (CNS), gastrointesti-
nal (GI), liver, kidney, metabolic, and cutane-
ous. The average rate for each event reported 
in the UK model was detailed for each indi-
vidual strategy, weighing it using the sever-
ity scores devised by a panel of clinicians 
(0 = no event, 5 = highest frequency). The 
data were broken down into the relative con-
tributions associated with the backbone and 
one specific third agent. The effects of the 
backbone and the third agent are additive in 
the first line (Table IX). For the subsequent 
lines when more than one third agent can be 
combined the assumption is made that the 
OIs and neoplasms α λ r2
Esophageal candidiasis 2.8952 0.00349 0.94
Kaposi sarcoma 2.5926 0.00359 0.99
Pulmonary tb 3.0467 0.00305 0.96
Non-hodgkins lymphoma 2.7559 0.00333 0.97
Extrapulmonary tuberculosis 2.3084 0.00359 0.95
Bacterial pneumonia 2.5499 0.00323 0.99
Pneumocystus jiroveccii pneumonia 1.0234 0.00472 0.98
Recurrent herpes simplex 2.4731 0.00313 0.97
HIV dementia 2.6290 0.00294 0.88
Cervical cancer1 1.7158 0.00242 0.96
Rare ADEs 2.3393 0.00279 0.94
HIV wasting syndrome 1.5530 0.00334 0.95
Progressive multifocal 
leukoencephalopathy
0.5390 0.00419 0.98
Toxoplasmosis of brain 0.3567 0.00436 0.96
Cytomegalovirus (non-retinitis) 2.6694 0.00173 0.98
Cryptosporidiosis 1.4919 0.00255 0.88
Mycobacterium avium complex 0.1371 0.00365 0.82
Cytomegalovirus retinitis -0.2564 0.00384 0.95
Cryptococcosis -0.7088 0.00417 0.96
Table VIII. Estimation of the exponential curves parameters for each type of 
infection or neoplasm
1 Only for female patients (in this case PYFU = 313,011)
The causes of virological failure were taken 
from the results of an analysis conducted in 
Portugal on 187 PLHIV [30]. For simplic-
ity, failures due to intolerance and pharma-
cokinetic interactions were aggregated into a 
single cause of virological failure since, it is 
assumed that they are managed in a similar 
way. Also, lost to follow-up was not consid-
ered a treatment failure, because the simula-
tion model maintained charge of all PLHIV. 
The rates thus calculated have been scaled 
down on the basis of the rates of resistance 
reported for PIs, NNRTIs and INIs (Table IV) 
[27].
Cambiano et al. [31] have highlighted a risk 
of late failure for patients who maintain vi-
ral suppression after 12 months of treatment, 
depending on adherence to treatment, on any 
previous failures due to drug resistance and 
on the class of the third agent. The relative 
risks for each risk factor are reported in Table 
V; the monthly rate of failure used as a refer-
ence (corresponding to a 100% adherence) is 
0.56%.
Evolution of CD4
The monthly value of the CD4 count is one 
of the main parameters for determining the 
risk of diabetes, renal damage, risk of OIs, 
neoplasms and mortality. The trend over time 
of the CD4 count for patients in virologi-
cal suppression was drawn from a cohort of 
ART-naïve [32] PLHIV, as a function of the 
CD4 count at the start of treatment, and the 
duration of treatment. The relation, which is 
non-linear, is expressed by the formula:
The regression coefficients are reported in 
Table VI.
For non-suppressed patients, a monthly re-
duction factor as a function of the baseline 
viral load [33], was applied to the CD4 val-
ue determined by the regression described 
above (Table VII).
Adverse events
Opportunistic Infections and neoplasms
The risks of OIs and neoplasms were calcu-
lated from exponential curves fitted to the 
data from more than 200,000 adults with 
HIV, with a Person-Years Follow-Up (PYFU) 
of 1,154,803, as a function of the CD4 count 
[34]. The monthly risk p was calculated 
through the formula:
Parameters Average sE
α 747.55 6.43
βyear 53.68 4.21
βCD4 (baseline CD4 count)
 • 500+ -177.92 9.32
 • 350-499 -270.35 8.57
 • 200-349 -368.46 8.79
 • 100-199 -449.20 8.65
 • 50-99 -481.46 8.94
 • 25-49 -522.19 9.01
βCD4year (baseline CD4 count
1)
 • 500+ 21.11 6.19
 • 350-499 14.37 5.48
 • 200-349 20.36 5.65
 • 100-199 20.40 5.59
 • 50-99 22.56 5.75
 • 25-49 32.61 5.91
Table VI. Coefficients related to the regression of the CD4 count
1 Term of interaction between baseline CD4 count and duration of treatment (in years)
SE = Standard Error
Baseline hIV viral load (log10) reduction in CD4 count
≤ 2.70 3.025
≤ 3.48 3.733
≤ 4.00 4.600
≤ 4.48 5.400
> 4.48 6.375
Table VII. Correction factor for the CD4 count in patients who do not achieve 
virological suppression
119Farmeconomia. Health economics and therapeutic pathways 2017; 18(1)
L. Pradelli, G. Di Perri, G. Rizzardini, E. Martelli, S. Giardina, M. Povero
where intercept ɑ and shape parameter λ are 
specific to each of the 19 AIDS-related dis-
orders highlighted in the study (Table VIII).
Treatment Related Adverse Events
Treatment-related adverse events (TRAEs) 
were divided into the following categories: 
central nervous system (CNS), gastrointesti-
nal (GI), liver, kidney, metabolic, and cutane-
ous. The average rate for each event reported 
in the UK model was detailed for each indi-
vidual strategy, weighing it using the sever-
ity scores devised by a panel of clinicians 
(0 = no event, 5 = highest frequency). The 
data were broken down into the relative con-
tributions associated with the backbone and 
one specific third agent. The effects of the 
backbone and the third agent are additive in 
the first line (Table IX). For the subsequent 
lines when more than one third agent can be 
combined the assumption is made that the 
OIs and neoplasms α λ r2
Esophageal candidiasis 2.8952 0.00349 0.94
Kaposi sarcoma 2.5926 0.00359 0.99
Pulmonary tb 3.0467 0.00305 0.96
Non-hodgkins lymphoma 2.7559 0.00333 0.97
Extrapulmonary tuberculosis 2.3084 0.00359 0.95
Bacterial pneumonia 2.5499 0.00323 0.99
Pneumocystus jiroveccii pneumonia 1.0234 0.00472 0.98
Recurrent herpes simplex 2.4731 0.00313 0.97
HIV dementia 2.6290 0.00294 0.88
Cervical cancer1 1.7158 0.00242 0.96
Rare ADEs 2.3393 0.00279 0.94
HIV wasting syndrome 1.5530 0.00334 0.95
Progressive multifocal 
leukoencephalopathy
0.5390 0.00419 0.98
Toxoplasmosis of brain 0.3567 0.00436 0.96
Cytomegalovirus (non-retinitis) 2.6694 0.00173 0.98
Cryptosporidiosis 1.4919 0.00255 0.88
Mycobacterium avium complex 0.1371 0.00365 0.82
Cytomegalovirus retinitis -0.2564 0.00384 0.95
Cryptococcosis -0.7088 0.00417 0.96
Table VIII. Estimation of the exponential curves parameters for each type of 
infection or neoplasm
1 Only for female patients (in this case PYFU = 313,011)
maximum probability for the specific third 
agents will be used.
Non-AIDS related morbidities
The risks of NARMs are calculated from 
regressions published in the literature, as a 
function of the patients’ baseline characteris-
tics and any antiretroviral treatments [9-12]; 
a similar regression for the risk of fractures 
was not found in the literature, therefore it 
was decided to act conservatively, using a 
non-treatment-specific, uniform fractures 
rate; the data – 10.3% [13] over a median 
follow-up of 6.19 years – was then converted 
into a monthly rate.
Mortality
The model considers three possible causes 
of death: mortality in the general popula-
tion, NARM-related mortality and mortality 
for OIs and neoplasms. It was assumed that 
regimen
Monthly frequency (%)
Cns gI liver Kidney Metabolic Cutaneous
TDF/FTC + ATV/r 0.1 2.2 0.7 1.3 2.0 0.1
ABC/3TC + ATV/r 0.1 2.2 0.6 0.6 1.0 0.1
TDF/FTC + DRV/r 0.0 2.5 0.6 0.9 1.9 0.3
ABC/3TC + DRV/r 0.0 2.5 0.6 0.1 0.9 0.3
TDF/FTC + RAL 0.0 1.4 0.1 0.8 1.1 0.1
ABC/3TC + RAL 0.0 1.5 0.1 0.0 0.1 0.1
TDF/FTC + DTG 0.7 1.2 0.1 0.8 1.1 0.1
ABC/3TC + DTG 0.7 1.2 0.1 0.0 0.1 0.1
TDF/FTC + EVG/c 0.0 1.3 0.1 1.1 3.1 0.1
E/C/F/TAF/ 0.0 1.3 0.1 0.0 3.1 0.1
TDF/FTC + ATV/r + DTG 0.8 2.2 0.7 1.3 2.0 0.2
ABC/3TC + ATV/r + DTG 0.8 2.2 0.6 0.6 1.1 0.2
TDF/FTC + DRV/r + RAL 0.0 2.8 0.6 0.9 2.0 0.3
ABC/3TC + DRV/r + RAL 0.0 2.8 0.6 0.1 1.0 0.3
TDF/FTC + DRV/r + DTG 0.7 2.5 0.6 0.9 2.0 0.3
ABC/3TC + DRV/r + DTG 0.7 2.5 0.6 0.1 1.0 0.3
TDF/FTC + ATV/r + ETV 0.4 2.5 0.7 1.3 2.1 0.7
ABC/3TC + ATV/r + ETV 0.4 2.5 0.7 0.6 1.1 0.7
TDF/FTC + DRV/r + RPV 0.0 2.6 0.9 0.9 1.9 0.3
ABC/3TC + DRV/r + RPV 0.0 2.6 0.9 0.2 0.9 0.3
TDF/FTC + DRV/r + ETV 0.3 2.8 0.7 0.9 2.0 0.9
ABC/3TC + DRV/r + ETV 0.3 2.8 0.6 0.1 1.0 0.8
TDF/FTC + ATV/r + RAL + MVC 0.1 2.4 0.7 1.3 2.1 0.2
ABC/3TC + ATV/r + RAL + MVC 0.1 2.4 0.7 0.6 1.1 0.2
TDF/FTC + ATV/r + DTG + MVC 0.8 2.2 0.7 1.3 2.1 0.2
ABC/3TC + ATV/r + DTG + MVC 0.8 2.2 0.7 0.6 1.1 0.2
TDF/FTC + DRV/r + RAL + MVC 0.0 2.8 0.7 0.9 2.0 0.3
ABC/3TC+DRV/r + RAL + MVC 0.0 2.8 0.6 0.1 1.0 0.3
TDF/FTC + DRV/r + DTG + MVC 0.7 2.5 0.7 0.9 2.0 0.3
ABC/3TC + DRV/r + DTG + MVC 0.7 2.5 0.6 0.1 1.0 0.3
Table IX. Monthly frequencies of TRAEs for all the regimens simulated in the analysis
CNS = Central Nervous System; GI = gastrointestinal
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(HR), adjusted for gender, age, CD4 count, 
baseline viral load and duration of disease.
In the case of NARMs, however, natural 
mortality [37] was adjusted for the event-spe-
cific Standardized Mortality Ratios (SMRs), 
which represented the possible increased risk 
of death in the group under observation in 
comparison to the general population. When 
possible, the data were differentiated by gen-
der (Table X). For patients with hypertension, 
no increase in the risk of death was assumed, 
because such disease is a risk factor included 
in other NARMs, such as CVD and diabetes.
Utility
The utility weights for patients with HIV were 
calculated using a linear regression based on 
age, gender, race, IDU and CD4 count [42]. 
To these weights, were then applied the util-
ity decrements related to the development of 
side effects [43-50] and HIV-related and -un-
related diseases [41,51-55].
Economic inputs
In the analysis, the following cost categories 
were taken into account:
 - Drug therapy for the treatment of HIV.
 - Hospitalization for OI/neoplasms.
 - Treatment of HIV-unrelated diseases.
 - Medical examinations and diagnostic 
procedures.
 - Treatment of side effects.
Drug therapy
The monthly cost of the treatments consid-
ered in the model were determined by taking 
the ex-factory price published in Italian Of-
ficial Gazette and the dosage recommended 
in the Summary of Product Characteristics 
(SPC). Should several packages of the same 
drug be available, it was decided to consider 
the one with the lowest cost. Data are sum-
marized in Table XI.
Hospitalizations for OIs/neoplasms
The management of the disease-related 
events (opportunistic infections and malig-
nant tumors) was valued through the tariffs 
for Diagnosed Related Group (DRG) 489 
(€ 8,186) and 490 (€ 2,458) [56]; specifi-
cally, DRG 490 was associated with: cervi-
cal cancer, rare adverse events, HIV wasting 
syndrome, progressive multifocal leukoen-
cephalopathy, cryptosporidiosis and myco-
bacterium avium complex, while DRG 489 
was associated with the remaining events.
HIV-unrelated adverse events
The disease costs for NARMs (diabetes, car-
diovascular events, renal damage, bone frac-
tures and hypertension) were calculated start-
ing from observational studies published in 
nArMs gender sMrs (mean value) sE
Diabetes [38] Male 1.31 0.01
Female 1.39 0.01
CVD [39] Male 1.36 0.14
Female 1.34 0.13
CKD [40] Both 4.70 0.10
Fracture [41] Both 7.47 0.75
Table X. Effect of non-AIDS related morbidities on mortality
CKD = Chronic Kidney Disease; CVD = cardiovascular; NARMs = Non-AIDS Related 
Morbidities SE = Standard Error; SMRs = Standardized Mortality Ratios
Drugs Dosage Monthly cost (€)
III agent
EFV 600 mg OD 162.90
RPV 25 mg OD 273.60
ETV 200 mg BID 450.00
DRV/r (in non-resistant regimens) 800 mg OD 504.001
DRV/r (in resistant patients) 600 mg BID 743.701
ATV/r 300 mg OD 414.001
RAL 400 mg BID 604.50
DTG (in non-resistant regimens) 50 mg OD 604.80
DTG (in resistant patients) 50 mg BID 1,209.60
MVC 300 mg 900.00
MVC 300 mg BID 1800.00
Backbone
TDF/FTC 445 mg OD 455
ABC/3TC 900 mg OD 381.00
Other1 270.34
sTr
TDF/FTC/EFV 1 TAB OD 664.72
TDF/FTC/RPV 1 TAB OD 728.46
TDF/FTC/EVG/c 1 TAB OD 1,059.50
TAF/FTC/EVG/c 1 TAB OD 1,059.50
Table XI. Daily dosage and monthly cost for each treatment considered in the 
model
1 Calculated as twice the weighted average of the main backbones for the 2014 UK market 
quotas [38] (such quotas have been used as a proxy in the absence of data for the Italian 
market)
BID = bis in die (twice a day); CNS = Central Nervous System; GI = gastrointestinal; 
/r = boosted with ritonavir (100-200 mg OD or BID, ex-factory € 24,00); OD = semel in die 
(once a day); STR = Single-Tablet antiretroviral Regimen
TRAEs are not one of the causes of death, 
in accordance with the results of Grant et al 
[35].
Mortality rates in case of opportunistic infec-
tions and neoplasms were obtained from an 
analysis conducted on 30,000 people living 
with HIV who had initiated HIV antiretrovi-
ral therapy [36]; these values  are expressed 
in risk rates in the case of events diagnosed 
within 6 months of treatment or, in the case 
of events diagnosed later, as a hazard ratio 
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the literature (Table XII) and converted into 
monthly costs.
Disease management
The cost of management of the HIV-positive 
patient was calculated considering the virol-
ogy tests and CD4 counts [56], adjusted for 
the annual frequency indicated by guidelines 
[8]. For each examination, a specialist visit 
for the evaluation of the results of the afore-
mentioned tests was also considered (Table 
XIII).
Management of side effects
Management of adverse events related to 
drug therapy was valued through the tariff 
for DRG 490 (HIV associated or not asso-
ciated to other related conditions) in outpa-
tient care; the cost per event is equal to € 
261 [56].
sensitivity analysis
The uncertainty of the parameters were tak-
en into account by means of a probabilistic 
sensitivity analysis: 100 simulations were 
performed, in each of which all input param-
eters were sampled by appropriate distribu-
tions fitted for the average values previously 
reported, and for the relative standard devia-
tions; for the input data for which variability 
measures were not available in the literature, 
a standard deviation – equal to 10% of the 
average value – was assumed.
Several one-way Deterministic Sensitivity 
Analyses (DSA) were also carried out, in or-
der to assess the impact of certain parameters 
Event Monthly cost (€) Description
Diabetes 257.69 Drugs, hospitalizations and specialist visits for the year 2010, updated to 2014 [57]
CVD 172.82 Drugs, hospitalizations and specialist visits for the year 2009, updated to 2014 [58]
Fracture 127.331 Hospitalizations and rehabilitation for fractures (femur/hip and others) [56,59-60]
CKD 146.23 Cost of the resources used, averaged for the distribution of severity stages in Italy [61]
Hypertension 61.09 Average cost of drug therapy [62]
Table XII. Monthly cost for the management of HIV-unrelated morbidities
1 The monthly cost was calculated assuming that the incidence of fractures is not greater than one per year
CKD = Chronic Kidney Disease; CVD = cardiovascular
Patient category Monthly cost (€) Description
Category 1 
(new patient)
45.76 Viral load (every 4/8 weeks for the first 6 months, then every 3/4 months) + CD4 count 
(2 consecutive ones at the beginning of therapy, then every 2/4 months) + visits to 
check the test results
Category 2 
(stable patient)
26.65 Viral load + CD4 count (every 3/4 months) + visits to check the test results
Category 3 
(critical patient)
65.79 Viral load (every 4/8 weeks) + CD4 count (every 1/2 months) + visits to check the test 
results
Table XIII. Cost of management of HIV patients
on the cost-effectiveness of ECF/TAF com-
pared to the comparators considered in this 
analysis:
 - To assess the impact of E/C/F/TAF on 
the short (5 years)/medium (10-30 years)/
long term (40 years), the time horizon of 
the simulation was varied from the mini-
mum case up to 40 years.
 - Discount rate for costs and benefits equal 
to 3-5%.
 - The cost of disease-related adverse events 
(OIs, neoplasms and TRAEs) was varied 
by ± 10%.
 - Two alternative adherence scenarios were 
considered in the sensitivity analysis:
 - The increase in adherence due to the STR 
was set to zero
 - For adherence data [1], an alternative 
source was used for the Italian context: 
92.4% for patients in suppression, 38.4% 
for patients who do not achieve suppres-
sion and increase in adherence due to the 
STRs equal to 6.6 %
results
Treatment with E/C/F/TAF was dominant 
over all comparators; in each case, E/C/F/
TAF produced better survival and better qual-
ity of life (20.17 LY and 14.89 QALY), with 
the lowest total cost (€ 280,528), (Table XIV 
and Figure 2). Pharmaceutical costs represent 
almost 90% of the total cost for the treatment 
of patients with HIV, followed by NARM 
costs – 6% of total.
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The sensitivity analysis confirmed the re-
sults of the base case: at a willingness-to-pay 
threshold of € 30,000 per QALY, the ECF/
TAF strategy was the most cost-effective, 
with a 90% probability; (Figure 3).
The results were stable under alternative as-
sumptions of discount rates, cost of man-
agement of adverse events and adherence to 
treatment (Table XV). However, when shorter 
time horizons were taken into account, the 
only change highlighted was the loss of domi-
nance of E/C/F/TAF vs. TDF/FTC-DRV/r (up 
to 10 years) and TDF/FTC-ATV/r (up to 20 
years) (Figure 4). For the initial drug therapy, 
in fact, the two treatments have lower acquisi-
tion costs, which in the short term are not yet 
offset by the higher costs due to the switch to 
subsequent lines, and by the costs of the man-
agement of adverse events and comorbidities.
E/C/F/TAF TDF/FTC-EVg/c TDF/FTC+DrV/r TDF/FTC+ATV/r
Total cost (€) 280,528 ± 7,621 283,908 ± 7,715 296,831 ± 14,759 283,846 ± 15,970
 • Drugs 247,011 ± 6,308 249,056 ± 6,376 260,675 ± 13,916 247,606 ± 15,152
 • TRAEs 2,983 ± 320 3,532 ± 378 3,753 ± 456 3,796 ± 467
 • OIs/neoplasms 7,856 ± 3,818 7,791 ± 3,849 7,812 ± 3,969 7,911 ± 4,028
 • NARMs 15,907 ± 1,562 16,835 ± 1,667 17,962 ± 1,757 17,887 ± 1,748
 • Disease management 6,771 ± 639 6,692 ± 631 6,628 ± 624 6,646 ± 626
QALY 14.89 ± 0.63 14.75 ± 0.62 14.54 ± 0.62 14.54 ± 0.62
Δ costs (€) - 3,379 ± 1,116 16,302 ± 15,576 3,318 ± 16,711
Δ QALY - -0.14 ± 0.03 -0.35 ± 0.05 -0.35 ± 0.05
ICER per QALY - Dominated Dominated Dominated
Table XIV. Results of the cost-effectiveness model: cost and effectiveness increases are calculated compared to E/C/F/TAF (data are 
reported as average ± SE; standard errors were derived from the results of the probabilistic sensitivity analysis)
NARMs = Non-AIDS Related Morbidities; OIs = Opportunistic Infections; TRAEs = Treatment-Related Adverse Events
Figure 2. Total cost and quality of life resulting from the analysis of the base case 
for E/C/F/TAF and the 3 comparators included in the analysis
Figure 3. Cost-effectiveness acceptability curves (CEAC): comparison between E/C/F/TAF and TDF/FTC-ATV/r. TDF/FTC in association 
with EVG/c or DRV/r does not appear in the comparison, since it wasn’t cost-effective for any WTP (Willingness-To-Pay) threshold
E/C/F/TAF
TDF/
FTC-EVg/c
TDF/
FTC+DrV/r
TDF/
FTC+ATV/r
Discount rate (3%)
Total cost (€) 303,254 306,759 321,651 307,981
QALY 16.02 15.86 15.62 15.62
Δ costs (€) 3,505 18,397 4,727
Δ QALY -0.16 -0.40 -0.40
ICER Dominated Dominated Dominated
Discount rate (5%)
Total cost (€) 226,966 229,943 238,553 227,445
QALY 12.19 12.10 11.95 11.96
Δ costs (€) - 2,978 11,587 479
Δ QALY - -0.09 -0.23 -0.23
ICER - Dominated Dominated Dominated
Cost of management of adverse events (-10%)
Total cost (€) 279,445 282,775 295,674 282,676
QALY 14.89 14.75 14.54 14.54
Δ costs (€) - 3,331 16,230 3,231
Δ QALY - -0.14 -0.35 -0.35
ICER - Dominated Dominated Dominated
Cost of management of adverse events (+10%)
Total cost (€) 281,612 285,040 297,987 285,017
QALY 14.89 14.75 14.54 14.54
Δ costs (€) - 3,428 16,375 3,405
Δ QALY - -0.14 -0.35 -0.35
ICER - Dominated Dominated Dominated
Alternative source for adherence
Total cost (€) 281,421 283,664 296,782 283,737
QALY 14.90 14.74 14.54 14.54
Δ costs (€) - 2,244 15,361 2,316
Δ QALY - -0.16 -0.36 -0.36
ICER - Dominated Dominated Dominated
Table XV. Results of the sensitivity analysis on discount rate, cost of 
management of adverse events and adherence to treatment: cost and 
effectiveness increases were calculated compared to E/C/F/TAF
Figura 4. Results of the sensitivity analysis for different assumptions of time horizon
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The sensitivity analysis confirmed the re-
sults of the base case: at a willingness-to-pay 
threshold of € 30,000 per QALY, the ECF/
TAF strategy was the most cost-effective, 
with a 90% probability; (Figure 3).
The results were stable under alternative as-
sumptions of discount rates, cost of man-
agement of adverse events and adherence to 
treatment (Table XV). However, when shorter 
time horizons were taken into account, the 
only change highlighted was the loss of domi-
nance of E/C/F/TAF vs. TDF/FTC-DRV/r (up 
to 10 years) and TDF/FTC-ATV/r (up to 20 
years) (Figure 4). For the initial drug therapy, 
in fact, the two treatments have lower acquisi-
tion costs, which in the short term are not yet 
offset by the higher costs due to the switch to 
subsequent lines, and by the costs of the man-
agement of adverse events and comorbidities.
E/C/F/TAF TDF/FTC-EVg/c TDF/FTC+DrV/r TDF/FTC+ATV/r
Total cost (€) 280,528 ± 7,621 283,908 ± 7,715 296,831 ± 14,759 283,846 ± 15,970
 • Drugs 247,011 ± 6,308 249,056 ± 6,376 260,675 ± 13,916 247,606 ± 15,152
 • TRAEs 2,983 ± 320 3,532 ± 378 3,753 ± 456 3,796 ± 467
 • OIs/neoplasms 7,856 ± 3,818 7,791 ± 3,849 7,812 ± 3,969 7,911 ± 4,028
 • NARMs 15,907 ± 1,562 16,835 ± 1,667 17,962 ± 1,757 17,887 ± 1,748
 • Disease management 6,771 ± 639 6,692 ± 631 6,628 ± 624 6,646 ± 626
QALY 14.89 ± 0.63 14.75 ± 0.62 14.54 ± 0.62 14.54 ± 0.62
Δ costs (€) - 3,379 ± 1,116 16,302 ± 15,576 3,318 ± 16,711
Δ QALY - -0.14 ± 0.03 -0.35 ± 0.05 -0.35 ± 0.05
ICER per QALY - Dominated Dominated Dominated
Table XIV. Results of the cost-effectiveness model: cost and effectiveness increases are calculated compared to E/C/F/TAF (data are 
reported as average ± SE; standard errors were derived from the results of the probabilistic sensitivity analysis)
NARMs = Non-AIDS Related Morbidities; OIs = Opportunistic Infections; TRAEs = Treatment-Related Adverse Events
Figure 2. Total cost and quality of life resulting from the analysis of the base case 
for E/C/F/TAF and the 3 comparators included in the analysis
Figure 3. Cost-effectiveness acceptability curves (CEAC): comparison between E/C/F/TAF and TDF/FTC-ATV/r. TDF/FTC in association 
with EVG/c or DRV/r does not appear in the comparison, since it wasn’t cost-effective for any WTP (Willingness-To-Pay) threshold
E/C/F/TAF
TDF/
FTC-EVg/c
TDF/
FTC+DrV/r
TDF/
FTC+ATV/r
Discount rate (3%)
Total cost (€) 303,254 306,759 321,651 307,981
QALY 16.02 15.86 15.62 15.62
Δ costs (€) 3,505 18,397 4,727
Δ QALY -0.16 -0.40 -0.40
ICER Dominated Dominated Dominated
Discount rate (5%)
Total cost (€) 226,966 229,943 238,553 227,445
QALY 12.19 12.10 11.95 11.96
Δ costs (€) - 2,978 11,587 479
Δ QALY - -0.09 -0.23 -0.23
ICER - Dominated Dominated Dominated
Cost of management of adverse events (-10%)
Total cost (€) 279,445 282,775 295,674 282,676
QALY 14.89 14.75 14.54 14.54
Δ costs (€) - 3,331 16,230 3,231
Δ QALY - -0.14 -0.35 -0.35
ICER - Dominated Dominated Dominated
Cost of management of adverse events (+10%)
Total cost (€) 281,612 285,040 297,987 285,017
QALY 14.89 14.75 14.54 14.54
Δ costs (€) - 3,428 16,375 3,405
Δ QALY - -0.14 -0.35 -0.35
ICER - Dominated Dominated Dominated
Alternative source for adherence
Total cost (€) 281,421 283,664 296,782 283,737
QALY 14.90 14.74 14.54 14.54
Δ costs (€) - 2,244 15,361 2,316
Δ QALY - -0.16 -0.36 -0.36
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Table XV. Results of the sensitivity analysis on discount rate, cost of 
management of adverse events and adherence to treatment: cost and 
effectiveness increases were calculated compared to E/C/F/TAF
Figura 4. Results of the sensitivity analysis for different assumptions of time horizon
conclusIons
The introduction of effective combination 
ART in 1996 significantly changed the clini-
cal course of HIV disease: the progression of 
the infection is now manageable with thera-
py, resulting in increased quality of life and 
much improved patient survival. Since treat-
ed HIV is now a lifelong conditions, its treat-
ments need to be increasingly focused on the 
long-term management of patient NARMs 
and avoiding/limiting treatment adverse ef-
fects. E/C/F/TAF meets these requirements 
by reducing the side effects associated with 
antiretroviral therapy, in addition to suppres-
sion of viral load. This allows for the optimal 
management of comorbidities, which are the 
consequence of a long exposure to virus-re-
lated risks, current treatments and advancing 
age.
Although several therapeutic options are 
available, the number of usable drugs is lim-
ited because of developed resistance, intoler-
ance or high risk of side effect. It is there-
fore essential to assign the most appropriate 
therapy to each patient, so as to minimize the 
risk of failure and maximize the lifespan of 
each regimen for each patient.
Although it is not possible to develop an ac-
tual decision-making algorithm to determine 
the most appropriate HAART therapy for a 
treatment-naïve patient, there are guideline 
recommendations. The Italian Guidelines 
recommend, without restrictions, certain 
regimens, including TDF/FTC and TAF/
FTC, in association with the integrase inhibi-
tor EVG/c and, under certain conditions, in 
combination with PIs boosted with ritonavir. 
Single tablet regimens are recommended by 
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a more effective and more efficient manage-
ment of patients living with HIV.
drug nAMe AbbrevIAtIons
 - 3TC = lamivudine
 - ABC = abacavir
 - ATV = atazanavir
 - DRV = darunavir
 - DTG = dolutegravir
 - E/C/F/TAF = Elvitegravir/Cobicistat/
Emtricitabine/Tenofovir Alafenamide 
Fumarate
 - EFV = efavirenz
 - ETV = etravirine
 - EVG = elvitegravir
 - FTC = emtricitabine
 - MVC = maraviroc
 - RAL = raltegravir
 - RPV = rilpivirine
 - TAF = Tenofovir Alafenamide Fumarate
 - TDF = Tenofovir Disoproxil Fumarate
 - TDF/FTC-ATV/r = Tenofovir Disoproxil 
Fumarate/emtricitabine + atazanavir 
boosted with ritonavir
 - TDF/FTC-DRV/r = Tenofovir Disoproxil 
Fumarate/emtricitabine + darunavir 
boosted with ritonavir
 - TDF/FTC-EVG/c = Tenofovir Disoproxil 
Fumarate/emtricitabine/elvitegravir 
boosted with cobicistat
 - /c = boosted with cobicistat
 - /r = boosted with ritonavir
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the Italian guidelines as a possible tool to 
simplify treatment, increase adherence to 
therapy and, consequently, improve the con-
trol of the disease.
ECF/TAF is therefore a viable alternative to 
other currently available treatments, combin-
ing the advantage of the STR with improved 
renal and bone safety than observed in regi-
mens including TDF [24].
The drawback of the success of antiretrovi-
ral therapy is the substantial expenditure in-
curred for lifelong treatment, and the need to 
resort to second, third and subsequent lines 
of treatment in case of failure. It is therefore 
important, for healthcare professionals and 
decision-makers, to investigate the cost-ef-
fectiveness of the new treatment options.
This analysis was aimed at assessing the 
cost-effectiveness profile of E/C/F/TAF ver-
sus TDF/FTC-EVG/c , and versus regimens 
consisting of TDF/FTC plus boosted daruna-
vir or atazanavir, which in recent years, in 
Italy, were the most commonly used ART 
regimens. The patient-level micro-simulation 
model developed was based on the available 
evidence derived from high-quality studies: 
comparative clinical inputs for the effective-
ness and tolerability data of ART regimens, 
national epidemiological characteristics and 
healthcare profiles, and economic parameters 
relevant to the NHS and clinical expert opin-
ion. The results indicate that ECF/TAF domi-
nates the alternatives considered: namely, it 
is associated with better clinical outcomes 
and with a concomitant saving of resources. 
This result derives from the highly effective 
suppression of viral load, greater adherence, 
thanks also to the STR formulation, com-
bined with improved safety and tolerability 
associated with TAF , the new component 
of this fixed-dose combination. This result is 
consistent with similar finding of a cost-effec-
tiveness analysis performed in the UK setting 
[7] in which E/C/F/TAF resulted dominant 
compared to TDF/FTC-EVG/c (£ 192,082 vs 
£ 195,274 with +0.06 QALY).Therefore use 
of E/C/F/TAF is a sustainable and cost-sav-
ing treatment option that can help to provide 
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